Discussion
A low dose of Vascarta‘s VAS-101, a curcumin-based gel being developed for sickle cell disease (SCD), was well tolerated and showed early signs of reducing red blood cell sickling, pain, and fatigue when administered under the tongue in a small Phase 1 study. The Phase 1 trial was…